Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

276.44
-13.6600-4.71%
Post-market: 276.440.00000.00%16:02 EDT
Volume:533.44K
Turnover:149.36M
Market Cap:7.70B
PE:-20.51
High:296.05
Open:291.59
Low:271.95
Close:290.10
52wk High:356.00
52wk Low:26.70
Shares:27.85M
Float Shares:25.78M
Volume Ratio:1.16
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.4758
EPS(LYR):-13.4758
ROE:-45.83%
ROA:-28.69%
PB:8.77
PE(LYR):-20.51

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 06, 2025

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Benzinga
·
Dec 06, 2025

Global Equities Roundup: Market Talk

Dow Jones
·
Dec 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana

Reuters
·
Dec 05, 2025

BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success

Reuters
·
Dec 05, 2025

Wedbush Adjusts Praxis Precision Medicines PT to $83 From $77, Maintains Underperform Rating

MT Newswires Live
·
Dec 05, 2025

Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 05, 2025

Praxis Precision Medicines Inc : Needham Raises Target Price to $304 From $250

THOMSON REUTERS
·
Dec 05, 2025

Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $303 From $270

THOMSON REUTERS
·
Dec 05, 2025

Praxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment

Dow Jones
·
Dec 05, 2025

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

Benzinga_recent_news
·
Dec 05, 2025

Praxis Precision Medicines Announces Positive Results From Embold Study for Relutrigine in Scn2a and Scn8a Developmental and Epileptic Encephalopathies

THOMSON REUTERS
·
Dec 05, 2025

Praxis Precision Medicines Inc - FDA Confirms Meeting to Review Data and Discuss Next Steps

THOMSON REUTERS
·
Dec 05, 2025

Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies

Reuters
·
Dec 05, 2025

Praxis Precision Medicines Inc - Expects Nda Submission Completion in Early 2026

THOMSON REUTERS
·
Dec 05, 2025

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

GlobeNewswire
·
Dec 05, 2025

Praxis Precision Medicines Grants Restricted Stock Units to New Employees

Reuters
·
Dec 04, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 04, 2025

Praxis Precision Med Price Target Maintained With a $250.00/Share by Needham

Dow Jones
·
Dec 01, 2025